Indication
Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension) Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Mysimba 8 MG/90 MG Comprimidos de Liberacion ProlongadaSpain · 8 mg + 90 mg · comprimido de liberación prolongada · Orexigen Therapeutics Ireland LimitedSame brand
- MysimbaCroatiaSame brand
- Mysimba 8 mg/90 mg tabletten met verlengde afgifteNetherlands · Tablet met verlengde afgifte · Orexigen Therapeutics Ireland Limited